These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21900040)

  • 1. Lytic and latent EBV gene expression in transplant recipients with and without post-transplant lymphoproliferative disorder.
    Kroll J; Li S; Levi M; Weinberg A
    J Clin Virol; 2011 Nov; 52(3):231-5. PubMed ID: 21900040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
    G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.
    Leung E; Shenton BK; Green K; Jackson G; Gould FK; Yap C; Talbot D
    Transpl Infect Dis; 2004 Dec; 6(4):156-64. PubMed ID: 15762933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
    Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
    Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
    Merlino C; Cavallo R; Bergallo M; Giacchino F; Bollero C; Negro Ponzi A; Cavallo G
    New Microbiol; 2003 Apr; 26(2):141-9. PubMed ID: 12737195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
    Ruf S; Behnke-Hall K; Gruhn B; Bauer J; Horn M; Beck J; Reiter A; Wagner HJ
    J Clin Virol; 2012 Mar; 53(3):186-94. PubMed ID: 22182950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases.
    Haque T; Chaggar T; Schafers J; Atkinson C; McAulay KA; Crawford DH
    J Med Virol; 2011 Feb; 83(2):311-6. PubMed ID: 21181928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute cellular rejection and Epstein-Barr virus-related post-transplant lymphoproliferative disorder in a pediatric lung transplant with low viral load.
    Calabrese F; Loy M; Lunardi F; Marino D; Aversa SM; Rea F
    Transpl Infect Dis; 2010 Aug; 12(4):342-6. PubMed ID: 20030794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of Epstein-Barr virus load in Argentinean transplant recipients using real-time PCR.
    Yancoski J; Danielian S; Ibañez J; Turconi A; Cuarterolo M; Zelazko M; Niesters Hubert GM
    J Clin Virol; 2004 Sep; 31(1):58-65. PubMed ID: 15288615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
    J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival.
    Wheless SA; Gulley ML; Raab-Traub N; McNeillie P; Neuringer IP; Ford HJ; Aris RM
    Am J Respir Crit Care Med; 2008 Nov; 178(10):1060-5. PubMed ID: 18755927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.
    Rea D; Fourcade C; Leblond V; Rowe M; Joab I; Edelman L; Bitker MO; Gandjbakhch I; Suberbielle C; Farcet JP
    Transplantation; 1994 Aug; 58(3):317-24. PubMed ID: 8053055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of serum EBV DNA and gammopathy with post-transplant lymphoproliferative disease.
    Rosselet A; Vu DH; Meylan P; Chaubert AS; Schapira M; Pascual M; Aubert V; Tissot JD; Duchosal MA
    Clin Transplant; 2009; 23(1):74-82. PubMed ID: 19200218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
    Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
    Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease.
    Montone KT; Hodinka RL; Salhany KE; Lavi E; Rostami A; Tomaszewski JE
    Mod Pathol; 1996 Jun; 9(6):621-30. PubMed ID: 8782198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients.
    Hopwood PA; Brooks L; Parratt R; Hunt BJ; Bokhari M; Thomas JA; Yacoub M; Crawford DH
    Transplantation; 2002 Jul; 74(2):194-202. PubMed ID: 12151731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of specific lytic and latent transcripts can help to predict the status of Epstein-Barr virus infection in transplant recipients with high virus load.
    Zawilinska B; Kosinska A; Lenart M; Kopec J; Piatkowska-Jakubas B; Skotnicki A; Kosz-Vnenchak M
    Acta Biochim Pol; 2008; 55(4):693-9. PubMed ID: 19015775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early evidence of lymphoproliferative disorder: post-transplant monitoring of Epstein-Barr infection in adult and pediatric patients.
    Gaeta A; Nazzari C; Verzaro S; Latte MC; Fabri G; Scateni S; Raggi C; Lubrano R; Mancini C
    New Microbiol; 2006 Oct; 29(4):231-41. PubMed ID: 17201089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.